Keywords: Celgene, Revlimid, Rituxan, Non-Hodgkin's lymphoma, Manatile cell lymphoma

Celgene presents positive new data on cancer drug Revlimid in combination with Rituxan

Article | 19 June 2011

Print This

USA-headquartered Celgene (Nasdaq: CELG) presented strong data from a Phase II study, conducted by investigators from the MD Anderson Cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in